Glossary
A
AAabstinence
abstinence syndrome
addict
addiction
ADIN
ADIS
administration - routes of
agonist
alcohol
amphetamines
ANCD
antagonist
anticraving agents
assessment
AUDIT
aversion therapy
B
barbituratesbehaviour change
benzodiazepines
binge
brain function
brief intervention
brief motivational interviewing
buprenorphine
C
cannabisCBT
CDSR
chroming
cocaine
Cochrane Library
communication style
comorbidity or dual diagnosis
controlled use
classes of psychoactive drugs
cravings
D
dependence – DSM–IV & ICD–10depressants
detox / detoxification
'doctor shopping'
drug abuse
drug interactions
drug-related behaviours and harms
drug states
E
‘E’ or ecstasyeducation (community focus)
education (patient focus)
education (schools)
effectiveness
efficacy
Evidence-based Practice (EBP)
F
FLAGS
follow-up
FRAMES
G
GABAGHB
gold standards
H
half-lifehallucinogens
harm minimisation
harm reduction
I
illicit drugsinhalants
interventions
intoxication
J
K
ketaminesL
LAAMlapse / lapse-relapse cycle
licit drugs
M
maintenancemaintenance pharmacotherapy
methadone
models of drug use
motivational interviewing
mesolimbic dopamine system / reward centre of the brain
N
National Drug Strategy (NDS)National Drug Strategy Household Survey (NDSHS)
NEPOD
neuro-adaptation
neurotransmitters
O
opioids / opiatesoverdose
P
party drugspatient-centred approach
patient information
patterns of drug use
pharmacotherapies
polydrug use
pregnancy and drugs
prevention - primary, secondary & tertiary
psychoactive drugs
Q
R
relapse / relapse preventionrisk / ‘at risk’ groups
S
saliencescreening tools
serotonin
setting limits
shared care
social rehabilitation
stages of change
stimulants
street language / names
supply reduction
T
THCTherapeutic Community (TC)
tolerance
treatment options / modalities